A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies
Latest Information Update: 22 Mar 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; IPH 6101 (Primary) ; Venetoclax (Primary)
- Indications Acute-Megakaryocytic-Leukemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
- 03 Dec 2024 According to Innate Pharma media release, data from the study will be presented at American Society of hematology (ASH) Annual Meeting.
- 28 Nov 2024 Planned End Date changed from 12 Feb 2029 to 13 Aug 2029.